Advertisement

International Journal of Hematology

, Volume 94, Issue 6, pp 583–584 | Cite as

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide

  • Yasuyoshi Morita
  • Takahiro Shimada
  • Terufumi Yamaguchi
  • Shinya Rai
  • Chikara Hirase
  • Masakatsu Emoto
  • Kentaro Serizawa
  • Yasuhiro Taniguchi
  • Mayuko Ojima
  • Yoichi Tatsumi
  • Takashi Ashida
  • Itaru Matsumura
Letter to the Editor
Lenalidomide plays a central role in the treatment of multiple myeloma (MM). Ozaki et al. [ 1] very recently reported two cases that had developed inflammatory reactions to lenalidomide. We also experienced three similar cases among eight cases treated in our hospital from August 2010 to July 2011 (Table  1).
Table 1

Clinical data and serum cytokine levels pre and post the lenalidomide treatment

Case no.

Age (year)

Sex

CRP (mg/dl)a

WBC (Lym)b (×103/mm3)

M-protein (g/dl)

IFN-γ

IL-1β

IL-2

IL-4

IL-6

IL-10

TNF-α

b-FGF

VEGF

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

1

78

M

17.7

6.8 (0.75)

4.1 (0.62)

5.89

1.78

<0.1

<0.1

<10.0

<10.0

<0.8

<0.8

9.6

6.8

200

8.0

4.0

4.0

12.2

1.5

<10.0

<10.0

443

479

2

69

F

1.08

5.5 (1.05)

3.5 (0.98)

3.83

2.99

<0.1

<0.1

<10.0

<10.0

<0.8

<0.8

N.A

N.A

9.0

4.2

5.0

3.0

2.9

1.8

<10.0

<10.0

822

902

3

75

M

15.7

3.7 (1.05)

5.9 (0.41)

1.51

1.02

<0.1

0.3

<10.0

<10.0

<0.8

<0.8

3.8

3.4

2.3

54.7

9.0

9.0

71.0

4.5

<10.0

<10.0

820...

Keywords

Dexamethasone Multiple Myeloma Lenalidomide Serum Cytokine Level Febrile Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

Drs. Matsumura I and Morita Y received a grant for research from Celgene Corporation. All other authors declare no conflicts of interest.

References

  1. 1.
    Ozaki S, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, et al. Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. Int J Hematol. 2011;93:257–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs. 2005;14:1411–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Quach H, Ritchie D, Stewart AK, Neason P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Dredge K, Marriott JB, Macdonald CD. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87:1166–72.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Yasuyoshi Morita
    • 1
  • Takahiro Shimada
    • 1
  • Terufumi Yamaguchi
    • 1
  • Shinya Rai
    • 1
  • Chikara Hirase
    • 1
  • Masakatsu Emoto
    • 1
  • Kentaro Serizawa
    • 1
  • Yasuhiro Taniguchi
    • 1
    • 2
  • Mayuko Ojima
    • 1
  • Yoichi Tatsumi
    • 1
  • Takashi Ashida
    • 1
  • Itaru Matsumura
    • 1
  1. 1.Division of Hematology, Department of Internal MedicineKinki University Faculty of MedicineOsaka-SayamaJapan
  2. 2.Department of Gastroenterology and Hematology, Faculty of MedicineMiyazaki UniversityKiyotakeJapan

Personalised recommendations